Proactiveinvestors Australia Adalta Ltd Proactiveinvestors Australia Adalta Ltd RSS feed en Wed, 24 Apr 2019 12:57:23 +1000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[Media files - AdAlta targeting human trials for lead i-body fibrosis candidate in under a year ]]> Mon, 18 Feb 2019 11:10:00 +1100 <![CDATA[News - AdAlta will outline fibrosis treatment progress during Proactive CEO Sessions ]]> AdAlta Ltd’s (ASX:1AD) is focused on developing treatments for fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), and this strategy will be outlined at this month’s Proactive CEO Sessions.

The biotechnology company aims to develop and commercialise its i-body technology platform that has generated a pipeline of i-bodies, with an initial focus on treating fibrotic diseases.

AdAlta’s CEO and director Sam Cobb will present at the Sydney CEO Session on Monday, February 18 and at the Melbourne session on Tuesday, February 19.

Cobb is the founding CEO of AdAlta and has more than 15 years’ experience in business development and commercialisation of early-stage scientific technologies.

IPF: irreversible, unpredictable and incurable

IPF is an irreversible, unpredictable and incurable disease with at least 1,500 Australians diagnosed each year. Only 20% of patients diagnosed survive five years.

AdAlta late last month announced improved cell line development results for its lead i-body fibrosis candidate, AD-214, which it is advancing toward clinical development.

Results ahead of expectations

Results are now above previously reported expression levels, at 3 grams per litre (g/L), up from the 1g/L reported in October 2018.

The improved results mean AdAlta remains on track with the development of the manufacturing process for AD-214.

It is on target to deliver Good Laboratory Practice (GLP) material for its four-week non-human primate toxicology study, which is expected to begin in July 2019 and be completed in second half of the year.

AdAlta is also on track to deliver Good Manufacturing Practice (GMP) material for its phase I human study which is expected to begin in January 2020.

Register for the CEO Sessions today to find out more.

Sydney details, Monday, February 18, 2019

Melbourne details, Tuesday, February 19, 2019

Also featuring at both sessions will be Kazia Therapeutics Ltd (ASX:KZA) and Peninsula Energy Ltd (ASX:PEN) while Theta Gold Mines Ltd (ASX:TGM) is on the Sydney program and Anatara Lifesciences Ltd (ASX:ANR) is on the Melbourne program.

Mon, 04 Feb 2019 16:52:00 +1100
<![CDATA[Media files - AdAlta manufacturing pulmonary fibrosis candidate in next quarter ]]> Wed, 09 Jan 2019 18:46:00 +1100 <![CDATA[News - AdAlta’s $4.25 million placement brings lead drug candidate closer to the clinic ]]> AdAlta Ltd (ASX:1AD) has raised $4.25 million via a placement of shares to sophisticated and institutional investors at a price of 30 cents each.

The funding will support the biotechnology company advance its lead i-body candidate, AD-214, toward clinical development.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases.

AD-214 is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

AdAlta will use the new funds for manufacturing and pre-clinical studies of AD-214 as well as internal research and development of new i-bodies.

AdAlta chairman Paul MacLeman said: “This new funding brings AD-214 closer to the clinic. We are grateful of the support of the institutional and sophisticated investors who participated in the placement.”

AdAlta chief executive officer Sam Cobb added: “Combined with our existing cash position and anticipated refundable R&D tax incentive, the company now believes it has the necessary funds to take our lead program, AD-214 through to the end of manufacturing, an important milestone for the lead ibody candidate”.

Fri, 13 Jul 2018 15:38:00 +1000